Vertex Pharmaceuticals (NASDAQ: VRTX) has brought in billions of dollars in earnings over time thanks to its leadership in the market for cystic fibrosis (CF) treatment. And along with partner CRISPR Therapeutics, Vertex recently won approval for another potential blockbuster -- this time, a gene-editing treatment for blood disorders.

These programs are significant and should help Vertex continue to boost revenue over time. But the opportunities don't stop there.

Vertex also is working on a candidate that addresses one of the world's most common problems: pain. The company is wrapping up a pivotal program now and expects to report data early next year. Could this potential product be a gold mine for Vertex?

Continue reading

Source Fool.com